Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Bionano Genomics, Inc.

Stage 2 · Advancing · week 4

As of Oct 22, 2026, Bionano Genomics is in Stage 2, the uptrend phase, now in week 4 (since Sep 28, 2026). It closed at $1.18, 38.9% below its 52-week high and below its 200-day average, which is falling.

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. More about the company

$1.18
-5.60% today
$13.9M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 18 in Medical Instruments & Supplies · #1 of 272 in Health Care

Is BNGO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 23w
S4 70w
S4 32w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 23w → S1 1w → S4 70w → S1 4w → S4 9w → S1 2w → S4 32w → S1 8w → S4 9w → S1 3w → S2 4w current
Total tracked: 166 weeks across 11 stage runs.

BNGO among Medical Instruments & Supplies38th of 51 by relative strength

All 51 →
Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#StockStageRS1M
1PLSEStage 2 · wk 3498+1.3%
2PDEXStage 2 · wk 3697−13.3%
3HBIOStage 2 · wk 1195+3.6%
4ATRCStage 2 · wk 1089−1.1%
5WSTStage 2 · wk 2482+4.8%
6BDXStage 2 · wk 1181+9.8%
7ICUIStage 3 · wk 181+3.1%
8OSURStage 3 · wk 875−4.8%
…38BNGOStage 2 · wk 429−30.6%
vs 52W High
-38.9%
$1.06 lo$1.93 hi
38.9% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 4
1w13w26w
Week 4, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
-6.0%
200 DMA: $1.25 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.38x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-30.6%
3M
+6.3%
6M
-2.5%
YTD
-25.8%
1Y
-37.9%
Scan Membership
Breakout Watch
Latest: 2022-12-07
4 appearances in last 60 days. First seen: 2020-12-30.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 4 · Vol 0.38x
2026-10-21S2
Wk 4 · Vol 0.10x
2026-10-20S2
Wk 4 · Vol 0.37x
2026-10-19S2
Wk 4 · Vol 0.11x
2026-10-16S2
Wk 3 · Vol 0.16x
2026-10-15S2
Wk 3 · Vol 0.08x
2026-10-14S2
Wk 3 · Vol 0.14x
2026-10-13S2
Wk 3 · Vol 0.16x
2026-10-12S2
Wk 3 · Vol 0.42x
2026-10-09S2
Wk 2 · Vol 0.11x
2026-10-08S2
Wk 2 · Vol 0.16x
2026-10-07S2
Wk 2 · Vol 0.11x
Moving averages & range
50 DMA
$1.38
200 DMA
$1.25
52W High
$1.93
52W Low
$1.06
5D Low
$1.18
Resistance levels (recent highs)
20d High
$1.73
60d High
$1.83
120d High
$1.83
250d High
$1.93
Next resistance
+46.6%
to 20d High
ROE
-83.6%
Profit margin -106.6%
Dividend Yield
0.00%
P/B 0.4

Bionano Genomics: quick answers

What stage is Bionano Genomics in?

As of Oct 22, 2026, Bionano Genomics (BNGO) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 28, 2026 and is in week 4. What the four stages mean

Is Bionano Genomics in an uptrend?

Yes. Bionano Genomics is in a Stage 2 uptrend. It trades 6.0% below its 200-day average, which is falling.

How far is Bionano Genomics from its 52-week high?

Bionano Genomics closed at $1.18 on Oct 22, 2026, 38.9% below its 52-week high of $1.93. Its 52-week low is $1.06.

How has Bionano Genomics performed over the past year?

As of Oct 22, 2026, Bionano Genomics is down 37.9% over the past year and down 25.8% so far in 2026.

Which sector and industry is Bionano Genomics in?

Bionano Genomics is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.